Contrast developer Guerbet has reported a strong rise in demand for its Dotarem (gadoterate meglumine) injection due to the pandemic and supply chain disruptions.
The company said it shipped more doses of the gadolinium-based MRI contrast agent in October than in any other monthly period since its U.S. release in 2013. Guerbet has delivered more than 120 million doses in 70 countries, it noted.
